Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.

× No keyword cloud information.

1 in total

1. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.

Authors: Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Tendani Gaolethe; Chipo Petlo; Shahin Lockman; Lewis B Holmes; Joseph Makhema; Roger L Shapiro
Journal: Lancet Glob Health Date: 2018-06-04 Impact factor: 26.763

1 in total

96 in total

1. Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.

Authors: Shin-Ichiro Hattori; Hironori Hayashi; Haydar Bulut; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Kazuya Hasegawa; Manabu Aoki; Arun K Ghosh; Hiroaki Mitsuya
Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191

2. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.

Authors: Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky
Journal: Ann Intern Med Date: 2019-04-02 Impact factor: 25.391

Review 3. Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Authors: Sean G Kelly; Mary Clare Masters; Babafemi O Taiwo
Journal: Infect Dis Clin North Am Date: 2019-06-22 Impact factor: 5.982

4. Fertility Intentions and Clinical Care Attendance Among Women Living with HIV in South Africa.

Authors: Katherine B Rucinski; Sheree R Schwartz; Kimberly A Powers; Brian W Pence; Benjamin H Chi; Vivian Black; Helen Rees; Audrey E Pettifor
Journal: AIDS Behav Date: 2020-06

5. A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia.

Authors: Babafunso Aderemi Adenuga; Timothy William Rennie
Journal: Drug Saf Date: 2019-07 Impact factor: 5.606

Review 6. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors: Alan N Engelman
Journal: J Biol Chem Date: 2019-08-29 Impact factor: 5.157

Review 7. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045

Review 8. HIV Eradication Strategies: Implications for the Central Nervous System.

Authors: Rebecca T Veenhuis; Janice E Clements; Lucio Gama
Journal: Curr HIV/AIDS Rep Date: 2019-02 Impact factor: 5.071

9. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

Authors: Emmanuel Ndashimye; Mariano Avino; Abayomi S Olabode; Art F Y Poon; Richard M Gibson; Yue Li; Adam Meadows; Christine Tan; Paul S Reyes; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Eric J Arts
Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790

10. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.

Authors: Max R O'Donnell; Nesri Padayatchi; Amrita Daftary; Catherine Orrell; Kelly E Dooley; K Rivet Amico; Gerald Friedland
Journal: Lancet HIV Date: 2019-03 Impact factor: 12.767